Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
69 hedge funds and large institutions have $163M invested in Stemline Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 19 closing their positions.
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
9% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 23
1% less funds holding
Funds holding: 70 → 69 (-1)
52% less capital invested
Capital invested by funds: $338M → $163M (-$175M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$9.64M |
| 2 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$6.3M |
| 3 |
AG
Artal Group
Luxembourg
|
+$4.54M |
| 4 |
Jennison Associates
New York
|
+$3.66M |
| 5 |
Millennium Management
New York
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$7.09M |
| 2 |
JP Morgan Chase
New York
|
-$6.47M |
| 3 |
CII
CR Intrinsic Investors
Stamford,
Connecticut
|
-$3.46M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$3.35M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$3.13M |
STML Hedge Fund Activity: Q4 2013 in Review
69 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2013, worth a combined $163M — down 52% from $338M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of STML and 18 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 21 added.
The largest buyer was Franklin Resources, adding an estimated $9.64M. The largest seller was Citadel Advisors, exiting entirely with an estimated $7.09M sold.
- 69 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2013, down from 70 in Q3 2013.
- Funds reported $163M of Stemline Therapeutics, Inc. stock for Q4 2013, down 52% quarter-over-quarter.
- 18 funds opened new Stemline Therapeutics, Inc. positions in Q4 2013 and 19 closed out, a net change of -1 holder.
- The largest Stemline Therapeutics, Inc. buyer in Q4 2013 was Franklin Resources, an estimated $9.64M added.
- The largest Stemline Therapeutics, Inc. seller in Q4 2013 was Citadel Advisors, an estimated $7.09M sold.
Based on aggregated 13F filings for Q4 2013.